Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020000 · ClinicalTrials.gov registry record
The Objective of the Protocol is to Generate Real World Evidence (RWE) Supporting the Safety, Performance, and Health Economics of Using the Regulatory Approved and Commercially Available EARP Interbody System Used During Lumbar Interbody Fusion (LIF) Procedures With the EARP Nerve Cuff Electrode
A clinical trial, sponsored by Retropsoas Technologies.
- Not yet
- Registry status
- 120
- Enrollment target
NCT07020000: Clinical Trial study, sponsored by Retropsoas Technologies.
NCT07020000 is a clinical trial that has not yet begun recruiting, run by Retropsoas Technologies. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07020000 has not yet begun recruiting, sponsored by Retropsoas Technologies.
- NOT YET RECRUITING
- Registry status
- 120 participants
- Enrollment target
Study Summary
The goal of the trial is to generate data to support the safety, performance, and cost effectiveness of using the EARP devices during Lumbar Interbody Fusion (LIF) procedures. The primary objectives are: * To evaluate the safety of the EARP surgical technique and devices during LIF surgeries. * To understand the EARP fusion system's ability to achieve fusion and improve disk space over time.
Primary Outcome
Radiographic measurements including X-Ray, CT Scans, and MRIs if available
Interventions
- DEVICE Device: Nerve Cuff and Retractor System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-08-30 |
| Est. Completion | 2027-09-30 |
What is known before NCT07020000 opens enrollment
NCT07020000 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Device: Nerve Cuff and Retractor System is the first listed.
NCT07020000 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07020000 about?
NCT07020000 is a clinical study titled "The Objective of the Protocol is to Generate Real World Evidence (RWE) Supporting the Safety, Performance, and Health Economics of Using the Regulatory Approved and Commercially Available EARP Interbody System Used During Lumbar Interbody Fusion (LIF) Procedures With the EARP Nerve Cuff Electrode". The goal of the trial is to generate data to support the safety, performance, and cost effectiveness of using the EARP devices during Lumbar Interbody Fusion (LIF) procedures. The primary objectives are: * To evaluate the safety of the EARP surgical technique and devices during LIF surgeries. * To...
What is the current status of trial NCT07020000?
This trial is currently not yet recruiting. The enrollment target is 120 participants. The study started on 2025-08-30. Estimated completion is 2027-09-30.
What interventions are being tested in trial NCT07020000?
The interventions under investigation include: Device: Nerve Cuff and Retractor System (DEVICE).
Who is sponsoring clinical trial NCT07020000?
This trial is sponsored by Retropsoas Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI